Antibody-drug conjugate · Cytotoxic, directed at integrin beta-6 (ITGB6) · developed by Seagen, a wholly owned subsidiary of Pfizer
Sigvotatug vedotin is an antibody-drug conjugate in which a humanized IgG1 antibody binds integrin beta-6 on tumor cells and delivers the microtubule-disrupting agent MMAE after internalization and linker cleavage. It is being studied in non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06758401 | Phase 3 | Non-Small Cell Lung Cancer | Recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Carcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)Non-Small Cell Lung Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →